- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: July 2016
- Public Summary Document (PSD) July 2016 PBAC Meeting - PDF
- Public Summary Document (PSD) July 2016 PBAC Meeting - Word
Mepolizumab – July 2016
Mepolizumab: 100 mg/10 mL vial, powder for injection, 1, Nucala®
Last updated
28 October 2016
